Resveratrol decreases Rad51 expression and sensitizes cisplatin‑resistant MCF‑7 breast cancer cells

Leon‑Galicia,I.; Diaz‑Chavez,J.; Albino‑Sanchez,M.  E.; Garcia‑Villa,E.; Bermudez‑Cruz,R.; Garcia‑Mena,J.; Herrera,L.  A.; García‑Carrancá,A.; Gariglio,P.

doi:10.3892/or.2018.6336

Resveratrol decreases Rad51 expression and sensitizes cisplatin‑resistant MCF‑7 breast cancer cells

Authors:
- I. Leon‑Galicia
- J. Diaz‑Chavez
- M. E. Albino‑Sanchez
- E. Garcia‑Villa
- R. Bermudez‑Cruz
- J. Garcia‑Mena
- L. A. Herrera
- A. García‑Carrancá
- P. Gariglio
View Affiliations

Affiliations: Biomedical Unit for Cancer Research, Virus and Cancer Laboratory, Department of Basic Research, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerologia (INCan), 14080 Mexico City, Mexico, Biomedical Unit for Cancer Research, Carcinogenesis Laboratory, Department of Basic Research, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerologia (INCan), 14080 Mexico City, Mexico, Department of Genetics and Molecular Biology, Center of Research and Advanced Studies (Cinvestav‑IPN), 07360 Mexico City, Mexico, Biomedical Unit for Cancer Research, Carcinogenesis Laboratory, Department of Basic Research, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerologia (INCan), 14080 Mexico City, Mexico, Biomedical Unit for Cancer Research, Virus and Cancer Laboratory, Department of Basic Research, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerologia (INCan), 14080 Mexico City, Mexico
Published online on: March 27, 2018 https://doi.org/10.3892/or.2018.6336
Pages: 3025-3033

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol (RES), a polyphenol compound with anti‑proliferative properties, has been previously evaluated for its beneficial effects against a variety of tumour cells. The current study elucidated the means by which RES enhances the anti‑proliferative effects of cisplatin (CIS) on MCF‑7 cells, focusing on the inhibitory effects on DNA repair of double‑strand breaks (DSBs). Chemoresistant MCF‑7 cells (MCF‑7R) were generated by continuous exposure to low concentrations of CIS (10 µM CIS‑IC40) during 5 passages, with the IC50 value increasing ~3‑fold. Using an MTT assay, we estimated the changes in IC50 for CIS in MCF‑7, T47‑D, MDA‑MB‑231 and MCF‑7R cells in the presence of RES. The relative transcript level of Nbs‑1, Mre‑11 and Rad‑50 genes was assessed using RT‑qPCR analysis. Rad51 and H2AX [pSer139] protein expression was determined by western blot analysis. RES at 50 and 100 µM significantly enhanced the anti‑proliferative effects of CIS in both MCF‑7 and MCF‑7R cells, decreasing the IC50 values for CIS to one‑tenth and one‑sixth, respectively. A total of 100 µM RES decreased the relative transcript levels of homologous recombination (HR) initiation complex components and the Rad51 protein level in MCF‑7 and MCF‑7R cells. After 48 h of CIS DNA damage, the levels of Rad51 protein increased, but this effect was inhibited by 100 µM RES. RES also maintained serine 139 phosphorylation of histone H2AX, suggesting that RES prevents the repair of DSBs. It was observed that RES exerts an antagonistic effect over CIS on the activation of Rad51 and sustained phosphorylation of H2AX. The results suggest that RES in combination with DNA damage‑based therapy has potential as a strategy to overcome resistance and provide much safer and more effective treatment for breast cancer.

View Figures

View References

1	Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature. 411:366–374. 2001. View Article : Google Scholar
2	Chaney SG and Sancar A: DNA repair: Enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst. 88:1346–1360. 1996. View Article : Google Scholar
3	Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A and Aloyz R: Chlorambucil drug resistance in chronic lymphocytic leukemia: The emerging role of DNA repair. Clin Cancer Res. 7:454–461. 2001.
4	Monneret C: Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr. 69:286–295. 2011. View Article : Google Scholar
5	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar
6	Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007. View Article : Google Scholar
7	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar
8	Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R and Panasci LC: In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst. 93:1473–1478. 2001. View Article : Google Scholar
9	Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE and Bristow RG: Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther. 8:203–213. 2009. View Article : Google Scholar
10	Ko JC, Ciou SC, Cheng CM, Wang LH, Hong JH, Jheng MY, Ling ST, Lin YW, Ko JC, Ciou SC, et al: Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis. 29:1448–1458. 2008. View Article : Google Scholar
11	Tsai MS, Kuo YH, Chiu YF, Su YC and Lin YW: Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 335:830–840. 2010. View Article : Google Scholar
12	Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC and Lin YW: Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp Cell Res. 315:2658–2672. 2009. View Article : Google Scholar
13	Javvadi P, Segan AT, Tuttle SW and Koumenis C: The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol. 73:1491–1501. 2008. View Article : Google Scholar
14	Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM and Lin YW: Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol. 79:655–664. 2010. View Article : Google Scholar
15	Fremont L: Biological effects of resveratrol. Life Sci. 66:663–673. 2000. View Article : Google Scholar
16	Sanders TH, McMichael RW Jr and Hendrix KW: Occurrence of resveratrol in edible peanuts. J Agric Food Chem. 48:1243–1246. 2000. View Article : Google Scholar
17	Sobolev VS and Cole RJ: Trans-resveratrol content in commercial peanuts and peanut products. J Agric Food Chem. 47:1435–1439. 1999. View Article : Google Scholar
18	Bianchini F and Vainio H: Wine and resveratrol: Mechanisms of cancer prevention? Eur J Cancer Prev. 12:417–425. 2003. View Article : Google Scholar
19	Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Zappia V and Della Ragione F: Resveratrol: From basic studies to bedside. Cancer Treat Res. 159:167–184. 2014. View Article : Google Scholar
20	Leon-Galicia I, Diaz-Chavez J, Garcia-Villa E, Uribe-Figueroa L, Hidalgo-Miranda A, Herrera LA, Alvarez-Rios E, Garcia-Mena J and Gariglio P: Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. Eur J Cancer Prev. 22:11–20. 2013. View Article : Google Scholar
21	Yalcin A: Quantification of thioredoxin mRNA expression in the rat hippocampus by real-time PCR following oxidative stress. Acta Biochim Pol. 51:1059–1065. 2004.
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
23	Mao Z, Jiang Y, Liu X, Seluanov A and Gorbunova V: DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia. 11:683–691. 2009. View Article : Google Scholar
24	Christodoulopoulos G, Malapetsa A, Schipper H, Golub E, Radding C and Panasci LC: Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res. 5:2178–2184. 1999.
25	Hine CM, Seluanov A and Gorbunova V: Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA. 105:20810–20815. 2008. View Article : Google Scholar
26	Maacke H, Hundertmark C, Miska S, Voss M, Kalthoff H and Sturzbecher HW: Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol. 128:219–222. 2002. View Article : Google Scholar
27	Richardson C: RAD51, genomic stability, and tumorigenesis. Cancer Lett. 218:127–139. 2005. View Article : Google Scholar
28	Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM and Hartley JA: Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol. 76:19–27. 2008. View Article : Google Scholar
29	Suwaki N, Klare K and Tarsounas M: RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol. 22:898–905. 2011. View Article : Google Scholar
30	Hussain SA, Sulaiman AA, Balch C, Chauhan H, Alhadidi QM and Tiwari AK: Natural polyphenols in cancer chemoresistance. Nutr Cancer. 68:879–891. 2016. View Article : Google Scholar
31	Mao QQ, Bai Y, Lin YW, Zheng XY, Qin J, Yang K and Xie LP: Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res. 54:1574–1584. 2010. View Article : Google Scholar
32	Vanamala J, Reddivari L, Radhakrishnan S and Tarver C: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer. 10:2382010. View Article : Google Scholar
33	Liu PL, Tsai JR, Charles AL, Hwang JJ, Chou SH, Ping YH, Lin FY, Chen YL, Hung CY, Chen WC, et al: Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol Nutr Food Res. 2:S196–S204. 2010. View Article : Google Scholar
34	Kraft TE, Parisotto D, Schempp C and Efferth T: Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr. 49:782–799. 2009. View Article : Google Scholar
35	Kelley MR, Logsdon D and Fishel ML: Targeting DNA repair pathways for cancer treatment: What's new? Future Oncol. 10:1215–1237. 2014. View Article : Google Scholar
36	Bouwman P and Jonkers J: The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Natu Rev Cancer. 12:587–598. 2012. View Article : Google Scholar
37	Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR and Bishop DK: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 275:23899–23903. 2000. View Article : Google Scholar
38	Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar
39	Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE and Lev D: Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: A role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther. 6:1650–1660. 2007. View Article : Google Scholar
40	Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R and Skorski T: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 8:795–806. 2001. View Article : Google Scholar
41	Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K and Tofilon PJ: Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63:7377–7383. 2003.
42	Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM and Buggy JJ: HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA. 104:19482–19487. 2007. View Article : Google Scholar
43	Shirode AB, Kovvuru P, Chittur SV, Henning SM, Heber D and Reliene R: Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks. Mol Carcinog. 53:458–470. 2014. View Article : Google Scholar
44	Sharma P, McClees SF and Afaq F: Pomegranate for prevention and treatment of cancer: An update. Molecules. 22:E1772017. View Article : Google Scholar
45	Le Corre L, Fustier P, Chalabi N, Bignon YJ and Bernard-Gallon D: Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin Chim Acta. 344:115–121. 2004. View Article : Google Scholar
46	Meng J, Guo F, Xu H, Liang W, Wang C and Yang XD: Combination therapy using Co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep. 6:223902016. View Article : Google Scholar
47	Ruivo J, Francisco C, Oliveira R and Figueiras A: The main potentialities of resveratrol for drug delivery systems. Braz J Pharm Sci. 51:499–513. 2015. View Article : Google Scholar
48	Singh G and Pai RS: Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: Optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv. 22:522–530. 2015. View Article : Google Scholar
49	Smoliga JM and Blanchard O: Enhancing the delivery of resveratrol in humans: If low bioavailability is the problem, what is the solution? Molecules. 19:17154–17172. 2014. View Article : Google Scholar
50	Uberti F, Morsanuto V, Aprile S, Ghirlanda S, Stoppa I, Cochis A, Grosa G, Rimondini L and Molinari C: Biological effects of combined resveratrol and vitamin D3 on ovarian tissue. J Ovarian Res. 10:612017. View Article : Google Scholar
51	Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H and Ahmad N: Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 55:1169–1176. 2011. View Article : Google Scholar
52	Frozza RL, Bernardi A, Paese K, Hoppe JB, da Silva T, Battastini AM, Pohlmann AR, Guterres SS and Salbego C: Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol. 6:694–703. 2010. View Article : Google Scholar
53	Androutsopoulos VP, Fragiadaki I, Spandidos DA and Tosca A: The resveratrol analogue, 3,4,5,4′trans-tetramethoxystilbene, inhibits the growth of A375 melanoma cells through multiple anticancer modes of action. Int J Oncol. 49:1305–1314. 2016. View Article : Google Scholar
54	Androutsopoulos VP, Fragiadaki I and Tosca A: Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4′-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 24:632–634. 2015. View Article : Google Scholar
55	Androutsopoulos VP, Ruparelia KC, Papakyriakou A, Filippakis H, Tsatsakis AM and Spandidos DA: Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: Atructural requirements for potency. Eur J Med Chem. 46:2586–2595. 2011. View Article : Google Scholar
56	Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP and Gescher AJ: Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br J Cancer. 90:736–744. 2004. View Article : Google Scholar
57	Canpolat C, Pearson P and Jaffe N: Cisplatin-associated hemolytic uremic syndrome. Cancer. 74:3059–3062. 1994. View Article : Google Scholar
58	Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med. 100:704–713. 1984. View Article : Google Scholar
59	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar
60	Osman AM, Telity SA, Damanhouri ZA, Al-Harthy SE, Al-Kreathy HM, Ramadan WS, Elshal MF, Khan LM and Kamel F: Chemosensitizing and nephroprotective effect of resveratrol in cisplatin -treated animals. Cancer Cell Int. 15:62015. View Article : Google Scholar
61	Valentovic MA, Ball JG, Brown JM, Terneus MV, McQuade E, Van Meter S, Hedrick HM, Roy AA and Williams T: Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicol In Vitro. 28:248–257. 2014. View Article : Google Scholar
62	Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, et al: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70:7392–7399. 2010. View Article : Google Scholar
63	Helleday T: Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis. 31:955–960. 2010. View Article : Google Scholar
64	Quiros S, Roos WP and Kaina B: Rad51 and BRCA2 - New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One. 6:e271832011. View Article : Google Scholar
65	Phuah NH and Nagoor NH: Regulation of microRNAs by natural agents: New strategies in cancer therapies. Biomed Res Int. 2014:8045102014. View Article : Google Scholar
66	Riffo-Campos AL, Riquelme I and Brebi-Mieville P: Tools for sequence-based miRNA target prediction: What to choose? Int J Mol Sci. 17:2016. View Article : Google Scholar
67	Wang Y, Huang JW, Calses P, Kemp CJ and Taniguchi T: MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 72:4037–4046. 2012. View Article : Google Scholar